R&D | May 21, 2026
QIAGEN and NVIDIA partner on AI drug discovery
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
BMS is moving beyond conversational AI into what it describes as “agentic” systems
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
The competition received over 42 entries from nursing colleges across Maharashtra
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
Subscribe To Our Newsletter & Stay Updated
